LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.

    Saeki, Yoshihiko / Saito, Mayumi / Irie, Takuya / Itoh, Fujiko / Enatsu, Akiko / Komura, Hiroko / Fujii, Miho / Fujii, Ryota / Hidaka, Natsuko / Maehama, Toshiyuki / Shirasu, Nobuhiko / Waseda, Tomoo / Shibata, Takeo / Takada, Emi / Mibe, Kazuki / Sakamoto, Jinichi / Yamada, Sousuke / Takakura, Masahiro / Sasagawa, Toshiyuki

    Journal of medical virology

    2024  Volume 96, Issue 2, Page(s) e29413

    Abstract: This study investigated the efficacy of the prophylactic human papillomavirus (HPV) vaccine, which was initiated between 2009 and 2013 in Japan. The study involved 1529 eligible women aged 16-39 years who visited 11 outpatient clinics in Japan for ... ...

    Abstract This study investigated the efficacy of the prophylactic human papillomavirus (HPV) vaccine, which was initiated between 2009 and 2013 in Japan. The study involved 1529 eligible women aged 16-39 years who visited 11 outpatient clinics in Japan for various reasons. These patients underwent HPV genotype analysis and a Pap test of cervical cell samples. A total of 299 women (19.6%) had received the prophylactic HPV vaccine (bivalent:quadrivalent vaccine ratio = 2:1). Of the 5062 participants in the Japanese Human Papillomavirus Disease Education and Research Survey (J-HERS 2011), which was conducted in the pre-vaccination era, 3236 eligible participants were included as controls. In this study (J-HERS 2021), the highest rate of HPV vaccination (53%) was observed in patients aged 22-27 years. Vaccinated individuals exhibited a 49% rate of protection against low-grade intraepithelial lesions (LSILs) and atypical squamous cells, not excluding high-grade squamous intraepithelial lesions (ASCH) or worse (LSIL/ASCH+), and a 100% rate of protection against high-grade squamous intraepithelial lesions (HSILs) or worse (HSIL+). Significant reductions in HPV16 (95%) and HPV18 (100%) infections were noted, but no differences were observed in HPV6 and HPV11 infections. The prevalences of HPV51 and HPV59 increased with vaccination, although these changes were not confirmed in the comparative study with J-HERS 2011. Comparing the prevaccination (J-HERS 2011) and postvaccination (J-HERS 2021) periods, 43%, 51%, 88%, and 62% reductions in HPV16, HPV18, HPV16/18, and HPV31/58 infection rates were observed, respectively. Similarly, 62% and 71% reductions in LSIL/ASCH+ and HSIL+ rates were noted, respectively. There were 88% and 87% reductions in LSIL/ASCH+ and HSIL+ rates in 16-21- and 28-33-year-old patients, respectively. Bivalent or quadrivalent vaccines provided 100% protection against high-grade squamous cell lesions (suggestive of CIN2 or CIN3) in young women aged <39 years at 9-12 years after initiation of Japan's first nationwide HPV vaccination program. Cross-protection against HPV31 and HPV58 is likely to occur, although some HPV-type replacements are inconsistent across vaccination regimens. This demonstrates the effectiveness of the HPV vaccine. However, continuous monitoring of cervical cancer and precancer is necessary in younger generations (born 1997-2007), who were rarely vaccinated due to the prolonged suspension of the vaccine recommendations in Japan.
    MeSH term(s) Humans ; Female ; Uterine Cervical Dysplasia ; Papillomavirus Vaccines ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/prevention & control ; Japan/epidemiology ; Human papillomavirus 16 ; Human papillomavirus 18 ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/prevention & control ; Uterine Cervical Neoplasms/pathology ; Papillomaviridae/genetics ; Squamous Intraepithelial Lesions ; Human papillomavirus 31 ; Vaccines, Combined
    Chemical Substances Papillomavirus Vaccines ; Vaccines, Combined
    Language English
    Publishing date 2024-02-03
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.29413
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced.

    Hasegawa, Keiko / Kobayashi, Reiko / Takada, Emi / Ono, Akiko / Chiba, Naoko / Morozumi, Miyuki / Iwata, Satoshi / Sunakawa, Keisuke / Ubukata, Kimiko

    The Journal of antimicrobial chemotherapy

    2006  Volume 57, Issue 6, Page(s) 1077–1082

    Abstract: Objectives: To study yearly changes in resistance and to identify ftsI mutations in beta-lactamase-non-producing ampicillin-resistant (BLNAR) and TEM-1 beta-lactamase-producing amoxicillin/clavulanic acid-resistant (BLPACR) isolates of Haemophilus ... ...

    Abstract Objectives: To study yearly changes in resistance and to identify ftsI mutations in beta-lactamase-non-producing ampicillin-resistant (BLNAR) and TEM-1 beta-lactamase-producing amoxicillin/clavulanic acid-resistant (BLPACR) isolates of Haemophilus influenzae from patients with meningitis.
    Methods: Between January 2000 and December 2004, we received 621 isolates of H. influenzae from 285 member institutions of the Nationwide Surveillance Study Group for Bacterial Meningitis. All isolates were analysed by PCR to identify resistance genes and tested for susceptibility to beta-lactams. The ftsI gene was sequenced in all BLNAR and BLPACR isolates.
    Results: All but four isolates were of serotype b. The isolates could be divided into six classes, namely beta-lactamase-non-producing ampicillin-susceptible (25.0%), TEM-1 beta-lactamase-producing ampicillin-resistant (11.0%), beta-lactamase-non-producing low-level ampicillin-resistant with N526K or R517H substitution in the ftsI gene (30.4%), BLNAR with an S385T substitution together with either N526K or R517H substitution in ftsI (22.2%), BLPACR-I with either a N526K or R517H substitution in ftsI (9.5%) and BLPACR-II with an S385T substitution together with either a N526K or R517H substitution in ftsI (1.9%). The prevalence of BLNAR has increased rapidly, from 5.8% in 2000 to 34.5% in 2004. All BLNAR and BLPACR-II strains were classified into nine subgroups on the basis of substitution patterns in the ftsI gene. The MICs of cephalosporin antibiotics for H. influenzae transformants into which the ftsI genes from BLNAR strains of each of the nine subgroups were introduced increased to varying degrees depending on the mutations.
    Conclusions: The results suggest that introduction of H. influenzae type b (Hib) vaccination into infants and children is necessary for the prevention of severe Hib infections in Japan.
    MeSH term(s) Amino Acid Substitution ; Ampicillin Resistance/genetics ; Anti-Bacterial Agents/pharmacology ; Child, Preschool ; DNA, Bacterial/analysis ; DNA, Bacterial/chemistry ; DNA, Bacterial/genetics ; Gene Transfer, Horizontal ; Genes, Bacterial ; Haemophilus influenzae type b/drug effects ; Haemophilus influenzae type b/enzymology ; Haemophilus influenzae type b/genetics ; Haemophilus influenzae type b/isolation & purification ; Humans ; Infant ; Japan ; Meningitis, Haemophilus/microbiology ; Microbial Sensitivity Tests ; Mutation ; Mutation, Missense ; Penicillin-Binding Proteins/genetics ; Polymerase Chain Reaction ; Sequence Analysis, DNA ; Transformation, Bacterial ; beta-Lactamases/analysis ; beta-Lactams/pharmacology
    Chemical Substances Anti-Bacterial Agents ; DNA, Bacterial ; Penicillin-Binding Proteins ; beta-Lactams ; beta-Lactamases (EC 3.5.2.6) ; beta-lactamase TEM-1 (EC 3.5.2.6)
    Language English
    Publishing date 2006-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkl142
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top